Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217386 · ClinicalTrials.gov registry record · Phase 2
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00217386 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00217386, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as anti-thymocyte globulin and etanercept, may stimulate the immune system in different ways and stop cancer cells from growing. Giving anti-thymocyte globulin together with etanercept may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together with etanercept works in treating patients with myelodysplastic syndromes.
Interventions
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217386
The ClinicalTrials.gov registry entry for NCT00217386 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which anti-thymocyte globulin is the first listed.
NCT00217386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217386 about?
NCT00217386 is a clinical study titled "Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes". RATIONALE: Biological therapies, such as anti-thymocyte globulin and etanercept, may stimulate the immune system in different ways and stop cancer cells from growing. Giving anti-thymocyte globulin together with etanercept may kill more cancer cells. PURPOSE: This phase II trial is studying how wel...
What is the current status of trial NCT00217386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00217386?
The interventions under investigation include: anti-thymocyte globulin (BIOLOGICAL), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00217386?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.